Can a smartwatch help control a common heart rhythm problem?
NCT ID NCT07445789
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two common heart rate-lowering drugs, verapamil and metoprolol, in 436 adults with paroxysmal atrial fibrillation (AF). It also tests whether using a smartwatch for self-care can reduce hospital visits and improve symptoms. The goal is to find better ways to manage AF and avoid emergency care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
verapamil or metoprolol
What this could lead to
If successful, this could show that verapamil or smartwatch-guided self-care reduces hospital visits and improves quality of life for people with paroxysmal atrial fibrillation.
What could go wrong
This is a phase 4 trial, so both drugs are already approved, but results may not apply to all AF patients. The smartwatch component depends on patient engagement and may not show clear benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••